Active Ingredient(s): Brodalumab
FDA Approved: * February 15, 2017
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Siliq Overview

Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1][2] In February 2017 it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.[3] Mechanism of action Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This me...

Read more Siliq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Siliq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 210mg/1.5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Siliq: (1 result)

Sorted by National Drug Code
  • 0187-0004 Siliq 210 mg Subcutaneous Injection by Valeant Pharmaceuticals North America LLC

Other drugs which contain Brodalumab or a similar ingredient: (1 result)